Anti-tumour and anti-metastatic activity of 3-(P-Chlorophenyl)-2,3-Dihydro-3-Hydroxythiazolo (3,2-A)-Benzimidazole-2-acetic acid (WY-13,876)
| Autor: | R L Fenichel, F J Gregory, H E Alburn |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1976 |
| Předmět: |
Male
Cancer Research Neoplasm Transplantation Benzimidazole Pathology medicine.medical_specialty Lung Neoplasms Cyclophosphamide medicine.medical_treatment T-Lymphocytes Antineoplastic Agents Pharmacology Median lethal dose Lethal Dose 50 chemistry.chemical_compound Mice polycyclic compounds medicine Neoplasm Animals heterocyclic compounds Neoplasm Metastasis Antilymphocyte Serum Anthelmintics Chemotherapy business.industry Neoplasms Experimental Levamisole medicine.disease Thiazoles Transplantation Isogeneic Oncology chemistry Fluorouracil Benzimidazoles business medicine.drug Research Article |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Extensive investigation of 3-(p-chlorophenyl)-2,3-dihydro-3-hydroxythiazolo(3,2-alpha)-benzimidazole-2-acetic acid (Wy-13,876) in BDF1 mice implanted with Lewis lung tumour has shown that it is an effective anti-tumour and anti-metastatic agent. In vitro examination using HEp-2 human epidermal tumour cells has indicated that Wy-13,876 is not cytotoxic. When mice implanted with Lewis lung tumour and treated with Wy-13,876 are also injected with anti-thymocyte serum, an increase in lung metastases is observed suggesting that thymocyte activity is involved in the drug's mechanism of action. An increase in peripheral T lymphocytes observed in rats 18 h after a single oral dose of Wy-13,876 further supports this possibility. When Wy-13,876 is given to tumour -bearing mice in combination with low, ineffective doses of 5-fluorouracil or cyclophosphamide, further reduction of primary tumour growth is observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|